Page 316 - Read Online

Page 14 of 19 Cervantes-Gracia et al. Vessel Plus 2020;4:27 I http://dx.doi.org/10.20517/2574-1209.2020.22

Signal 2014;20:1126-67.
3. Kim YM, Kim SJ, Tatsunami R, Yamamura H, Fukai T, et al. ROS-induced ROS release orchestrated by Nox4, Nox2, and mitochondria
in VEGF signaling and angiogenesis. Am J Physiol - Cell Physiol 2017;312:C749-64.
4. Chelombitko MA. Role of reactive oxygen species in inflammation: a minireview. Moscow Univ Biol Sci Bull 2018;73:199-202.
5. Yang W, Tao Y, Wu Y, Zhao X, Ye W, et al. Neutrophils promote the development of reparative macrophages mediated by ROS to
orchestrate liver repair. Nat Commun 2019;10:1076.
6. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
7. Cai Z, Yan LJ. Protein oxidative modifications: beneficial roles in disease and health. J Biochem Pharmacol Res 2013;1:15-26.
8. Cobley JN, Husi H. Immunological techniques to assess protein thiol redox state: opportunities, challenges and solutions. Antioxidants
2020;9:31.
9. Ranneh Y, Ali F, Akim AM, Hamid HA, Khazaai H, et al. Crosstalk between reactive oxygen species and pro-inflammatory markers in
developing various chronic diseases: a review. Appl Biol Chem 2017;60:327-38.
10. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol
Med 2010;49:1603-16.
11. Austin V, Crack PJ, Bozinovski S, Miller AA, Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing
links? Clin Sci 2016;130:1039-50.
12. Rovira-Llopis S, Rocha M, Falcon R, de Pablo C, Alvarez A, et al. Is myeloperoxidase a key component in the ROS-induced vascular
damage related to Nephropathy in type 2 diabetes? Antioxidants Redox Signal 2013;19:1452-8.
13. Hansen PR. Chronic inflammatory diseases and atherosclerotic cardiovascular disease: innocent bystanders or partners in crime? Curr
Pharm Des 2018;24:281-90.
14. Lorenzatti AJ, Servato ML. New evidence on the role of inflammation in CVD risk. Curr Opin Cardiol 2019;34:418-23.
15. Cervantes Gracia K, Llanas-Cornejo D, Husi H. CVD and oxidative stress. J Clin Med 2017;6:22.
16. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Eur
Heart J 2018;39:3021-104.
17. Vasan RS, Short MI, Niiranen TJ, Xanthakis V, DeCarli C, et al. Interrelations between arterial stiffness, target organ damage, and
cardiovascular disease outcomes. J Am Heart Assoc 2019;8:e012141.
18. Briasoulis A, Bakri GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep 2013;15:340.
19. Yuan J, Zou XR, Han SP, Cheng H, Wang L, et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease
patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 2017;18:23.
20. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health.
Ann Glob Health 2014;80:69-76.
21. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia
2016;8:56-61.
22. Rahman M, Xie D, Feldman HI, Go AS, He J, et al. Association between chronic kidney disease progression and cardiovascular disease:
results from the CRIC study. Am J Nephrol 2014;40:399-407.
23. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am J Roentgenol 2004;183:1673-89.
24. Pyxaras SA, Sinagra G, Mangiacapra F, Perkan A, Di Serafino L, et al. Contrast-induced nephropathy in patients undergoing primary
percutaneous coronary intervention without acute left ventricular ejection fraction impairment. Am J Cardiol 2013;111:684-8.
25. Sato A, Aonuma K, Watanabe M, Hirayama A, Tamaki N, et al. Association of contrast-induced nephropathy with risk of adverse clinical
outcomes in patients with cardiac catheterization: from the CINC-J study. Int J Cardiol 2017;227:424-9.
26. Rear R, Bell RM, Hausenloy DJ, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. Heart
2016;102:638-48.
27. Hossain MA, Costanzo E, Cosentino J, Patel C, Qaisar H, et al. Contrast-induced nephropathy: pathophysiology, risk factors, and
prevention. Saudi J Kidney Dis Transpl 2018;29:1-9.
28. McDonald JS, McDonald RJ, Tran CL, Kolbe AB, Williamson EE, et al. Postcontrast acute kidney injury in pediatric patients: a cohort
study. Am J Kidney Dis 2018;72:811-8.
29. Demirtas L, Turkmen K, Kandemir FM, Ozkaraca M, Kucukler S, et al. The possible role of interleukin-33 as a new player in the
pathogenesis of contrast-induced nephropathy in diabetic rats. Ren Fail 2016;38:952-60.
30. Oweis AO, Alshelleh SA, Daoud AK, Smadi MM, Alzoubi KH. Inflammatory milieu in contrast-induced nephropathy: a prospective
single-center study. Int J Nephrol Renovasc Dis 2018;11:211-5.
31. Yildirim E, Ermis E, Cengiz M. Inflammatory markers of contrast-induced nephropathy in patients with acute coronary syndrome. Coron
Artery Dis 2020;31:279-83.
32. Murashima M, Nishimoto M, Kokubu M, Hamano T, Matsui M, et al. Inflammation as a predictor of acute kidney injury and mediator of
higher mortality after acute kidney injury in non-cardiac surgery. Sci Rep 2019;9:20260.
33. de Souza Santos V, Peters B, Côco LZ, Alves GM, de Assis ALEM, et al. Silymarin protects against radiocontrast-induced nephropathy in
mice. Life Sci 2019;228:305-15.
34. Kim JE, Bae SY, Ahn SY, Kwon YJ, Ko GJ. The role of nuclear factor erythroid-2-related factor 2 expression in radiocontrast-induced
nephropathy. Sci Rep 2019;9:2608.
35. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, et al. World Health Organization cardiovascular disease risk charts:
revised models to estimate risk in 21 global regions. Lancet Glob Health 2019;7:e1332-45.